SFZN Siegfried Holding AG
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Siegfried Holding (SWX: SFZN)
›
Siegfried Holding (SWX: SFZN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 4,454 employees.
The shares were at 67.45 CHF on 19 November 2026, down 11.5% over 52 weeks. Its 52-week range is 65.05 CHF to 101.60 CHF: the price is 33.6% below the high and 3.7% above the low.
At a market capitalisation of 2.95B CHF, it trades at 17.3 times trailing earnings and 14.4 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 30% for SFZN. It pays a dividend yielding 0.59% (it pays out 10% of its earnings), against a median of 1.90% among the dividend payers in that peer group.
Siegfried Holding reports return on equity of 15.0%, an operating margin of 16.7% and revenue up 2.2% year over year.
Its debt exceeds its cash by 820.04M CHF. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 12 analysts cover the stock, with an average rating of Buy; their mean price target of 98.92 CHF is 46.7% above the current price. The next earnings report is expected on 23 February 2027.